Microstructured Lipid Carriers (MLC) Based on N-Acetylcysteine and Chitosan Preventing Pseudomonas aeruginosa Biofilm

被引:9
作者
Guerini, Marta [1 ]
Grisoli, Pietro [1 ]
Pane, Cristina [1 ]
Perugini, Paola [1 ]
机构
[1] Univ Pavia, Dept Drug Sci, Via Taramelli 12, I-27100 Pavia, Italy
关键词
microstructured lipid carriers; N-acetylcysteine; chitosan; biofilm; Pseudomonas aeruginosa; antioxidant activity; cystic fibrosis; CYSTIC-FIBROSIS; ANTIOXIDANT ACTIVITY; NANOPARTICLES; PHARMACOKINETICS; INFLAMMATION; TEMPERATURE; MONOTHERAPY; MECHANISMS; STABILITY; CYSTEINE;
D O I
10.3390/ijms22020891
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this work was the development of microstructured lipid carriers (MLC) based on chitosan (CH) and containing N-acetylcysteine (NAC), a mucolytic and antioxidant agent, to inhibit the formation of Pseudomonas aeruginosa biofilm. MLC were prepared using the high shear homogenization technique. The MLC were characterized for morphology, particle size, Z potential, encapsulation efficiency and drug release. The antioxidant properties of NAC-loaded microstructured carriers were evaluated through an in vitro spectrophotometer assay. Finally, the activity of NAC-CH-MLC on biofilm production by Pseudomonas aeruginosa was also evaluated. Results obtained from this study highlighted that the use of chitosan into the inner aqueous phase permitted to obtain microstructured particles with a narrow size range and with good encapsulation efficiency. NAC-loaded MLC showed higher antioxidant activity than the free molecule, demonstrating how encapsulation increases the antioxidant effect of the molecule. Furthermore, the reduction of biofilm growth resulted extremely high with MLC being 64.74% +/- 6.2% and 83.74% +/- 9.95%, respectively, at 0.5 mg/mL and 2 mg/mL. In conclusion, this work represents a favorable technological strategy against diseases in which bacterial biofilm is relevant, such as cystic fibrosis.
引用
收藏
页码:1 / 22
页数:21
相关论文
共 64 条
[1]   Freeze-drying of nanoparticles: Formulation, process and storage considerations [J].
Abdelwahed, Wassim ;
Degobert, Ghania ;
Stainmesse, Serge ;
Fessi, Hatem .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (15) :1688-1713
[2]   Folic acid loaded lipid nanocarriers with promoted skin antiaging and antioxidant efficacy [J].
Ammar, Hussein Osman ;
Ghorab, Mahmoud Mohamed ;
Mostafa, Dina Mahmoud ;
Ibrahim, Eman Samy .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2016, 31 :72-82
[3]   Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC) [J].
Ates, Burhan ;
Abraham, Linu ;
Ercal, Nuran .
FREE RADICAL RESEARCH, 2008, 42 (04) :372-377
[4]   N-Acetylcysteine -: a safe antidote for cysteine/glutathione deficiency [J].
Atkuri, Kondala R. ;
Mantovani, John J. ;
Herzenberg, Leonard A. ;
Herzenberg, Leonore A. .
CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (04) :355-359
[5]   Vibrational Spectroscopy Fingerprinting in Medicine: from Molecular to Clinical Practice [J].
Balan, Vera ;
Mihai, Cosmin-Teodor ;
Cojocaru, Florina-Daniela ;
Uritu, Cristina-Mariana ;
Dodi, Gianina ;
Botezat, Doru ;
Gardikiotis, Ioannis .
MATERIALS, 2019, 12 (18)
[6]   Pseudomonas aeruginosa Biofilms in the Respiratory Tract of Cystic Fibrosis Patients [J].
Bjarnsholt, Thomas ;
Jensen, Peter Ostrup ;
Fiandaca, Mark J. ;
Pedersen, Jette ;
Hansen, Christine Ronne ;
Andersen, Claus Bogelund ;
Pressler, Tacjana ;
Givskov, Michael ;
Hoiby, Niels .
PEDIATRIC PULMONOLOGY, 2009, 44 (06) :547-558
[7]  
Bleve M., 2010, INT J PHARM PHARM SC, V2, P37
[8]  
Bondet V, 1997, FOOD SCI TECHNOL-LEB, V30, P609
[9]   PHARMACOKINETICS OF N-ACETYLCYSTEINE IN MAN [J].
BORGSTROM, L ;
KAGEDAL, B ;
PAULSEN, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :217-222
[10]   CFTR structure and cystic fibrosis [J].
Cant, Natasha ;
Pollock, Naomi ;
Ford, Robert C. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 52 :15-25